Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13250268 | 0.98 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTTKCNA3 | |
| SCHEMBL6446538 | 0.95 | SMYD2 (0.38) | SMYD2SMN1; SMN2CYP3A4HTTKCNA3 | |
| SCHEMBL1316789 | 0.88 | SMYD2 (0.39) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL24312364 | 0.85 | SMN1; SMN2 (0.40) | SMYD2SMN1; SMN2CYP3A4HTTKCNA3 | |
| SCHEMBL5488886 | 0.85 | LTA4H (0.42) | SMYD2SMN1; SMN2CYP3A4HTTLTA4H | |
| SCHEMBL3933299 | 0.83 | SMN1; SMN2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL4863255 | 0.83 | IDO1 (0.42) | SMYD2SMN1; SMN2CYP3A4HTTKCNA3 | |
| SCHEMBL16888352 | 0.83 | SOAT1 (0.41) | SMYD2SMN1; SMN2CYP3A4HTTLTA4H | |
| SCHEMBL15426891 | 0.83 | SOAT1 (0.41) | SMYD2SMN1; SMN2CYP3A4HTTLTA4H | |
| SCHEMBL15566115 | 0.83 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTTKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543879-A1 | PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER | University College Cardiff Consultants Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024003533-A1 | PROTACS FOR TARGETED DEGRADATION OF KAT2A AND KAT2B FOR THE TREATMENT OF CANCER | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2024-01-04 | — | — | WO | disclosed |
| EP-0419610-B1 | NEW LEUKOTRIENE B4 DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-09-15 | — | — | EP | disclosed |
| EP-0419610-A1 | NEW LEUKOTRIENE B4 DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR USE AS DRUGS. | SCHERING AG (DE) | 1991-04-03 | — | — | EP | disclosed |
| WO-1990011271-A1 | NEW LEUKOTRIENE B4 DERIVATIVES, PROCESS FOR PRODUCING THEM AND THEIR USE AS DRUGS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1990-10-04 | — | — | WO | disclosed |